Connection

IRINA AGOULNIK to Mice

This is a "connection" page, showing publications IRINA AGOULNIK has written about Mice.
Connection Strength

0.371
  1. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology. Biochem Pharmacol. 2024 09; 227:116401.
    View in: PubMed
    Score: 0.064
  2. Expression patterns and the roles of phosphatidylinositol phosphatases in testis?. Biol Reprod. 2022 10 11; 107(4):902-915.
    View in: PubMed
    Score: 0.057
  3. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.043
  4. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.036
  5. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One. 2013; 8(4):e60455.
    View in: PubMed
    Score: 0.029
  6. Androgen receptor footprint on the way to prostate cancer progression. World J Urol. 2012 Jun; 30(3):279-85.
    View in: PubMed
    Score: 0.026
  7. Structure-Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2. J Med Chem. 2026 Mar 12; 69(5):5956-5985.
    View in: PubMed
    Score: 0.018
  8. Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2. Commun Biol. 2022 11 04; 5(1):1183.
    View in: PubMed
    Score: 0.014
  9. INPP4B protects from metabolic?syndrome and associated disorders. Commun Biol. 2021 03 26; 4(1):416.
    View in: PubMed
    Score: 0.013
  10. Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice. PLoS One. 2020; 15(5):e0233163.
    View in: PubMed
    Score: 0.012
  11. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 11; 33(11):12435-12446.
    View in: PubMed
    Score: 0.011
  12. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry. 2016 Mar 29; 55(12):1772-83.
    View in: PubMed
    Score: 0.009
  13. Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nat Commun. 2013; 4:1953.
    View in: PubMed
    Score: 0.007
  14. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.006
  15. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.006
  16. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod. 2007 Oct; 77(4):671-80.
    View in: PubMed
    Score: 0.005
  17. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.005
  18. A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet. 2000 Dec; 26(4):490-4.
    View in: PubMed
    Score: 0.003
  19. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma. 1999 Feb; 18(1):93-7.
    View in: PubMed
    Score: 0.003
  20. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res. 1997 Mar-Apr; 17(2A):811-3.
    View in: PubMed
    Score: 0.002
  21. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996 May; 61(2):175-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.